| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Total Assets  | 1,203 | 1,563 | 1,879 | 2,677 | 2,983 | 3,228 | 3,714 | 4,513 | 4,905 | 5,521 | 6,253 |
| Fixed Assets | 617 | 560 | 644 | 777 | 944 | 1,204 | 1,332 | 1,541 | 1,911 | 2,096 | 2,867 |
| Current Assets | 500 | 818 | 828 | 1,187 | 1,282 | 1,629 | 1,997 | 2,505 | 2,574 | 2,905 | 3,116 |
| Capital Work in Progress | 62 | 77 | 267 | 515 | 496 | 294 | 239 | 356 | 239 | 272 | 437 |
| Investments | 0 | 70 | 108 | 157 | 210 | 19 | 19 | 20 | 21 | 22 | 1,343 |
| Other Assets | 524 | 856 | 859 | 1,229 | 1,332 | 1,711 | 2,123 | 2,596 | 2,733 | 3,132 | 0 |
| Total Liabilities | 1,203 | 1,563 | 1,879 | 2,677 | 2,983 | 3,228 | 3,714 | 4,513 | 4,905 | 5,521 | 6,253 |
| Current Liabilities | 415 | 655 | 787 | 878 | 897 | 893 | 1,173 | 1,642 | 1,814 | 2,082 | 2,003 |
| Non Current Liabilities | 357 | 247 | 188 | 495 | 557 | 491 | 367 | 284 | 256 | 213 | 534 |
| Total Equity | 431 | 662 | 904 | 1,304 | 1,530 | 1,844 | 2,173 | 2,587 | 2,835 | 3,226 | 3,716 |
| Reserve & Surplus | 411 | 613 | 881 | 1,279 | 1,504 | 1,818 | 2,149 | 2,562 | 2,811 | 3,201 | 3,691 |
| Share Capital | 20 | 22 | 23 | 25 | 25 | 25 | 25 | 25 | 24 | 24 | 24 |
Granules
492.60
+2.45
(0.50%)
Market Cap
11,952.60 Cr
EPS
20.69
PE Ratio
24.95
Dividend Yield
0.30 %
Industry
Healthcare52 Week High
721.00
52 Week Low
422.00
PB Ratio
3.22
Debt to Equity
0.40
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
A unit of Granules India has completed a pre-approval inspection by the U.S. Food and Drug Administration (FDA). The inspection resulted in one 483 observation, which has been resolved. No further details about the specific unit, location, or nature of the observation were provided in the news snippet.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,676.30 | #1 4,02,200.50 | 35.07 | #1 52,041.20 | 12.06 | #1 10,980 | -18.99 | 48.33 | |
6,906.50 | 1,83,345.90 | 83.65 | 9,360.00 | 0.89 | 2,117 | 23.05 | 68.54 | |
1,513.30 | 1,22,230.40 | 23.76 | 28,409.50 | 7.12 | 5,291 | 30.28 | 54.26 | |
3,368.00 | 1,13,988.40 | 59.12 | 11,317.00 | 11.59 | 2,054 | 10.91 | 62.08 | |
1,307.40 | 1,09,111.80 | #1 19.63 | 33,741.20 | 12.36 | 5,725 | 21.14 | 54.13 | |
1,001.00 | 1,00,724.00 | 21.57 | 22,573.80 | 13.82 | 3,977 | -0.19 | 69.99 | |
2,439.50 | 1,00,685.20 | 50.68 | 12,207.40 | 19.57 | 1,925 | -10.91 | 59.65 | |
1,980.90 | 90,466.80 | 27.51 | 22,192.10 | #1 19.94 | 3,024 | #1 112.49 | 53.08 | |
34,735.00 | 73,809.50 | 52.20 | 6,409.15 | 10.80 | 1,417 | 27.83 | 64.97 | |
1,191.30 | 69,190.90 | 20.01 | 31,378.10 | 17.55 | 3,366 | -0.50 | 63.70 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
-0.33 %
Net Income Growth
-21.54 %
Cash Flow Change
-40.52 %
ROE
-31.01 %
ROCE
-21.01 %
EBITDA Margin (Avg.)
-6.98 %
Balance Sheet
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 24 | 75 | -82 | 66 | -25 | 103 | -144 | 143 | 107 | 90 |
| Investing Activities | -146 | -162 | -326 | -462 | -270 | -160 | -277 | -379 | -192 | -358 |
| Operating Activities | 150 | 151 | 188 | -1 | 262 | 476 | 433 | 332 | 739 | 439 |
| Financing Activities | 19 | 86 | 56 | 529 | -17 | -213 | -299 | 190 | -440 | 8 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Oct 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 42.04 % | 42.04 % | 42.04 % | 41.98 % | 41.98 % | 41.98 % | 41.93 % | 42.02 % | 42.02 % | 42.02 % | 42.02 % | 41.96 % | 41.96 % | 41.96 % | 38.87 % | 38.87 % | 38.85 % | 38.84 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 19.57 % | 20.39 % | 19.49 % | 15.87 % | 15.15 % |
| DIIs | 1.50 % | 2.86 % | 2.77 % | 4.34 % | 3.97 % | 3.03 % | 4.32 % | 4.23 % | 4.76 % | 5.03 % | 6.68 % | 6.85 % | 10.14 % | 10.70 % | 14.12 % | 14.86 % | 19.57 % | 22.45 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 26.21 % | 29.74 % | 27.00 % | 24.99 % | 24.55 % | 25.26 % | 21.72 % | 21.60 % | 20.74 % | 21.13 % | 21.91 % | 21.11 % | 20.39 % | 19.38 % | 18.78 % | 18.29 % | 17.45 % | 16.07 % |
| Others | 30.26 % | 25.36 % | 28.19 % | 28.69 % | 29.49 % | 29.73 % | 32.03 % | 32.15 % | 32.49 % | 31.82 % | 29.39 % | 30.07 % | 27.51 % | 8.39 % | 7.84 % | 8.49 % | 8.27 % | 7.50 % |
| No of Share Holders | 0 | 1,93,871 | 2,61,165 | 2,39,520 | 2,16,385 | 2,10,785 | 2,14,539 | 2,16,055 | 2,02,329 | 1,90,894 | 2,01,054 | 2,07,055 | 1,90,691 | 1,82,142 | 1,79,870 | 2,02,198 | 1,77,554 | 1,69,802 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.9 | 1 | 1 | 1 | 1.5 | 1.5 | 1.5 | 1.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.87 | 0.87 | 0.7 | 0.33 | 0.49 | 0.52 | 0.35 | 0.31 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 07 Aug 2025 |  Annual General Meeting | NA | 07 Aug 2025 | 522.05 | 492.80 |
| 31 Jul 2025 |  Dividend | ₹ 1.50 /share | 31 Jul 2025 | 522.05 | 492.80 |
| 28 May 2025 |  Quarterly Result Announcement | NA | 28 May 2025 | 453.15 | 522.05 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 608.80 | 582.35 |
| 06 Nov 2024 | Quarterly Result Announcement | NA | 06 Nov 2024 | 593.25 | 576.30 |
| 06 Aug 2024 | Annual General Meeting | NA | 06 Aug 2024 | 396.15 | 648.70 |
| 30 Jul 2024 | Dividend | ₹ 1.50 /share | 30 Jul 2024 | 396.15 | 587.80 |
| 03 Aug 2023 | Dividend | ₹ 1.50 /share | 03 Aug 2023 | 288.00 | 318.20 |
| 21 Jul 2022 | Dividend | ₹ 0.75 /share | 19 Jul 2022 | 263.05 | 308.70 |
| 18 Feb 2022 | Dividend | ₹ 0.25 /share | 17 Feb 2022 | 309.90 | 303.05 |
| 25 Nov 2021 | Dividend | ₹ 0.25 /share | 24 Nov 2021 | 311.35 | 315.00 |
| 06 Aug 2021 | Dividend | ₹ 0.25 /share | 05 Aug 2021 | 364.70 | 378.55 |
| 30 Jul 2021 | Dividend | ₹ 0.75 /share | 28 Jul 2021 | 359.90 | 379.40 |
| 09 Feb 2021 | Dividend | ₹ 0.25 /share | 08 Feb 2021 | 353.55 | 326.90 |
Announcements
Update
7 days ago
7 days agoClosure of Trading Window9 days ago
9 days agoUpdateJun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 17, 2025
Jun 17, 2025Transcript Of Earnings Conference Call For Q4 Of FY25Jun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 28, 2025
May 28, 2025Record Date For Payment Of Final Dividend For FY25May 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025
May 28, 2025Audited Financial Results For The Quarter And Financial Year Ended On March 31 2025May 28, 2025
May 28, 2025Outcome Of The Board MeetingMay 28, 2025
May 28, 2025Board Meeting Outcome for Outcome Of The Board MeetingMay 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 07, 2025
May 07, 2025Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results For The FY Ended March 31 2025 And Recommendation Of Final Dividend If Any.May 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Change in Registered Office AddressApr 20, 2025
Apr 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 10, 2025
Apr 10, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 07, 2025
Apr 07, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 25, 2025
Mar 25, 2025Board Meeting Outcome for Outcome Of The Board MeetingMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 20, 2025
Mar 20, 2025UpdateMar 18, 2025
Mar 18, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Mar 03, 2025
Mar 03, 2025Update Under Regulation 30Feb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 28, 2025
Feb 28, 2025UpdatesFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 21, 2025
Feb 21, 2025Board Meeting Outcome for Outcome Of The Board MeetingFeb 21, 2025
Feb 21, 2025UpdateFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Jan 30, 2025Transcript Of Earnings Conference Call For Q3 Of FY25Jan 30, 2025
Jan 30, 2025UpdateJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Jan 24, 2025Integrated Filing (Financial)Jan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 24, 2025
Jan 24, 2025Un-Audited Financial Results For The Quarter & Nine-Months Ended On December 31 2024Jan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 09, 2025
Jan 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 09, 2025
Jan 09, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2024.Jan 08, 2025
Jan 08, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 17, 2024
Dec 17, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 17, 2024
Dec 17, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 10, 2024
Dec 10, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 09, 2024
Dec 09, 2024UpdateDec 04, 2024
Dec 04, 2024Technical Indicators
RSI(14)
Neutral 44.93
ATR(14)
Less Volatile 12.91
STOCH(9,6)
Neutral 47.11
STOCH RSI(14)
Neutral 61.05
MACD(12,26)
Bearish -1.53
ADX(14)
Weak Trend 19.38
UO(9)
Bearish 40.47
ROC(12)
Downtrend And Accelerating -0.46
WillR(14)
Neutral -64.30
Mutual Fund Holdings
Kotak Arbitrage Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
HDFC Arbitrage Fund Wholesale Direct-Growth 
Axis India Manufacturing Fund Direct-Growth 
Old Bridge Focused Fund Direct - Growth 
Aditya Birla Sun Life Arbitrage Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
DSP Arbitrage Fund Direct - Growth 
Nippon India Arbitrage Fund Direct-Growth 
Mirae Asset Arbitrage Fund Direct - Growth 
Tata Arbitrage Fund Direct - Growth 
Franklin India Arbitrage Fund Direct-Growth 
Edelweiss Arbitrage Fund Direct-Growth 
Bandhan Arbitrage Fund Direct-Growth 
ICICI Prudential Equity Arbitrage Direct-Growth 
HSBC Arbitrage Fund Direct-Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth About Granules
Granules India Limited is a vertically integrated pharmaceutical company founded in 1991. It manufactures Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company specializes in off-patent drugs and first-line defense products like Paracetamol, Ibuprofen, Metformin, and Guaifenesin. Granules India operates seven manufacturing facilities, six in India and one in the US, serving over 300 customers across 80 countries. The company has a strong focus on research and development, with a dedicated R&D center in Hyderabad. Granules India has expanded its operations through acquisitions, capacity enhancements, and the establishment of subsidiaries. It has received various regulatory approvals and certifications for its facilities and products. The company has filed numerous ANDAs, DMFs, and CEPs, and has launched several generic products in the US market.
Chairperson NameC Krishna Prasad
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
